All three pillars are getting squeezed
24/03/20 -"Against the background of the to-be-expected recession, management's lifted dividend proposal of €1.30 per share looks far too optimistic, but, one has to bear in mind, the company is family-owned ..."
Pages
73
Language
English
Published on
24/03/20
You may also be interested by these reports :
25/11/25
CureVac’s Q3 sales surpassed market expectations, driven by a one-off contribution from GSK. The operating profit benefited from the resolution of ...
25/11/25
Even though the sentiment around Novo has been extremely adverse (further exacerbated by today’s R&D development around Alzheimer’s), in our opinion, ...
21/11/25
Ever since Sandoz demerged from Novartis, the generics/biosimilars giant has been delivering on its promises, and remains well on track to achieve ...
19/11/25
AstraZeneca has been beating the street’s estimates over the last few quarters, on the back of strong growth momentum for its oncology, rare disease, ...